What’s the current market cap for Johnson & Johnson stock?

Johnson & Johnson (JNJ) has a market cap of $560bn as of June 08, 2026.

What is the P/E ratio for Johnson & Johnson stock?

The price to earnings (P/E) ratio for Johnson & Johnson (JNJ) stock is 26.96 as of June 08, 2026.

Does Johnson & Johnson stock pay dividends?

Yes, the Johnson & Johnson (JNJ) stock pays dividends to shareholders. As of June 08, 2026, the dividend rate is $5.2 and the yield is 2.23%. Johnson & Johnson has a payout ratio of 59.52% on a trailing twelve-month basis.

When is the next Johnson & Johnson dividend payment date?

The next Johnson & Johnson (JNJ) dividend payment is scheduled for June 09, 2026.

What is the beta indicator for Johnson & Johnson?

Johnson & Johnson (JNJ) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Johnson & Johnson stock | $JNJ Share Price

13:30

15:10

16:45

18:25

20:00

About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Ticker

$JNJ

Sector

Health

Primary listing

NYSE

Employees

138,200

Headquarters

New Brunswick, United States

Website

www.jnj.com

JNJ Metrics

BasicAdvanced

$560bn

26.96

$8.64

0.26

$5.20

2.23%

What the Analysts think about JNJ

Analyst ratings (Buy, Hold, Sell) for Johnson & Johnson stock.

Bulls say / Bears say

Johnson & Johnson reported Q1 2026 revenue of $24.1 billion, an increase of nearly 10% year-over-year and above analysts’ expectations of $23.6 billion.

Cancer drug Darzalex generated $4.0 billion in Q1 and immunology treatment Tremfya brought in $1.6 billion, both well above consensus forecasts, showing strong demand across the oncology and immunology portfolios.

Management raised its full-year 2026 revenue outlook midpoint to about $100.8 billion and increased adjusted EPS guidance to $11.55 per share, reflecting confidence in ongoing growth.

Stelara’s Q1 2026 sales fell about 60% from a year earlier to $656 million after its patent expired and biosimilar competitors entered the market, highlighting the company's vulnerability to loss of exclusivity.

In December 2025, a Baltimore jury ordered Johnson & Johnson to pay a record $1.5 billion in a talc-related cancer lawsuit, and the company faces more than 67,000 pending talc claims, presenting significant risks from litigation and reserves.

Johnson & Johnson’s deals for most-favored-nation drug pricing threaten to cap U.S. list prices, which could limit future revenue growth and put pressure on margins in its biggest market.

Data summarised monthly by Lightyear AI. Last updated on 13 May 2026.

JNJ Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

JNJ Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $JNJ

Capital at risk

Market closed

Upcoming events

Bulls say / Bears say

Johnson & Johnson reported Q1 2026 revenue of $24.1 billion, an increase of nearly 10% year-over-year and above analysts’ expectations of $23.6 billion.

Management raised its full-year 2026 revenue outlook midpoint to about $100.8 billion and increased adjusted EPS guidance to $11.55 per share, reflecting confidence in ongoing growth.

Johnson & Johnson’s deals for most-favored-nation drug pricing threaten to cap U.S. list prices, which could limit future revenue growth and put pressure on margins in its biggest market.

Data summarised monthly by Lightyear AI. Last updated on 13 May 2026.